Check out this CME moderated by Terry Kim, Chief of Cornea for Duke Ophthalmology.
Dry eye disease (DED) is a condition of the ocular surface in which multiple factors are responsible for the disturbance of the stability of tear film, leading to changes in vision and symptoms that significantly disrupt the quality of life of many individuals in the United States and elsewhere. The American Academy of Ophthalmology estimates that 1 million to 4.3 million people in the United States aged between 65 and 84 have dry eye. Cyclosporine has been the prototype anti-inflammatory selective drug used to treat DED and was the first drug approved by the US Food and Drug Administration (FDA) to improve the production of tears in patients with DED. Most recently, lifitegrast ophthalmic solution 5% was the first drug approved by the FDA for the treatment of signs and symptoms of patients with DED. This activity will examine novel advances in diagnostic modalities to more accurately assess DED, as well as evaluate therapeutic agents for the management of dry eye.